Key result
NuPulseCV iVAS achieves ~89% 30-day stroke-free survival or transplant in advanced heart failure.
Why the study?
Following a first-in-human trial, the feasibility, clinical outcomes, and quality of life of the NuPulseCV intravascular ventricular assist system (iVAS) for extended ambulatory counterpulsation as a bridge to transplant or decision in advanced heart failure required further evaluation.
Answers are grounded in this paper and cite their sources.
Should not yet change practice in advanced HF; extends device data but remains hypothesis-generating pending randomized trials.
BACKGROUND: The NuPulseCV intravascular ventricular assist system (iVAS) provides extended duration ambulatory counterpulsation via a durable pump placed through the distal subclavian artery. METHODS: We performed a prospective, single-arm, multicenter, US Food and Drug Administration-approved feasibility trial of iVAS therapy as a bridge to transplant or decision following the FIH (First-In-Human) trial. RESULTS: Forty-seven patients were enrolled, and 45 patients (median 61 years old, 37 males, and 30 listed on United Network of Organ Sharing) received iVAS support for median 44 (25-87) days. There were no intraoperative complications. Success was defined as survival or transplant on iVAS therapy free from disabling stroke. Outcome success at 30 days (the primary end point of this study) and at 6 months was 89% and 80%, respectively. During 6 months of iVAS support, 2 patients died and 2 patients experienced disabling neurological dysfunction. Six-minute walk distance, 2-minute step test, and Kansas City Cardiomyopathy Questionnaire score improved during 4-week iVAS support. CONCLUSIONS: This feasibility trial demonstrated promising short-term outcomes of iVAS therapy with improved functional capacity and quality of life during the therapy. Registration: URL: http://www.clinicaltrials.gov. Unique identifier: NCT02645539.
No takes yet. Share an insight, caveat, or question.
Uriel et al. (2020) studied Advanced heart failure (n=45). NuPulseCV intravascular ventricular assist system (iVAS) was evaluated on Outcome success at 30 days (survival or transplant on iVAS therapy free from disabling stroke). NuPulseCV iVAS therapy achieved 89% outcome success (survival or transplant free from disabling stroke) at 30 days and 80% at 6 months in advanced heart failure.
Synapse has enriched 10 related papers. Consider them for comparative context: